CDMO/CMO
Drawing on various vaccine manufacturing technologies and expertise,
SK bioscience collaborates with other institutions and companies
that seek to produce vaccines in vaccine development, R&D collaboration, and CMO.
SK bioscience collaborates with other institutions and companies
that seek to produce vaccines in vaccine development, R&D collaboration, and CMO.
Development
- Process development
- Up-stream, down-stream and assay developments
- Clinical batch production
- Scale-up study & process validation
Manufacturing
- Up-stream and down-stream process for commercialization
- Viral vaccine/bacterial vaccine
- Final product (PFS, vial, oral drop, freeze-drying) & packaging
Project management
- Streamlined project management capability from development to commercial supply
Partnership
- Clinical research and development
- Co-development and manufacturing agreement
- Drug substance production
- Drug product production & quality lab
Viral Area
- Cell culture-based manufacturing capability from 10L to 2,000L, including single-use bioreactors.
- ACFM for adherent culture using automatic CF40
- Continuous ultra/high/low speed centrifugation
- BSL2 BSL3 design including bio-kill system
- Chromatography system & UF/DF skid
- Approved for commercial production by WHO PQ
- Upstream, downstream & analytical development
We are working with various global companies and foundations for global healthcare.
Pre-emption of
Manufacturing FacilitiesCEPI logo
Manufacturing FacilitiesCEPI logo
COVID-19
Extended contract of exclusive manufacturing facilities for the manufacturing of vaccine components designated by CEPI between 2020 and 2022
CDMONOVAVAX logo
COVID-19
Agreement for development & supply for NVX-CoV2373 antigen components
CMOAstraZeneca logo
COVID-19
Agreement for supply for ADZ1222 antigen components